Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the prospects for bringing innovation to Belgian patients and explains how BMS continues to deliver on its promise of transforming lives through science amidst the COVID-19 pandemic.
We want to combine the agility of a biotech with the experience of a Big Pharma company
Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up…
Pierre Fabre Benelux General Manager Kristel de Bisschop discusses the challenges and opportunities inherent in taking charge of an important affiliate against the backdrop of a group-wide transformation push and…
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest and most developed nations are represented, other smaller countries are punching…
While 2020 may have seemed like the year the world stood still for many, the pharma industry went into overdrive, working around the clock to ensure security of supply as…
The new Belgian government has moved to streamline its response to the COVID-19 crisis with the appointment of Pedro Facon, director general for health at Belgium’s Federal Public Service Health…
See our Cookie Privacy Policy Here